Kythera Biopharmaceuticals Inc.’s (KYTH) share price has entered into oversold territory with an RSI value of 28.9. The Zacks Consensus Estimate on Kythera Biopharmaceuticals Inc.’s earnings for the full year period has profit of 0.18 cents over the past two months to $-2.74 per share. Currently, Kythera Biopharmaceuticals Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (KYTH) after its recent drop.
KYTHERA BIOPHARMACEUTICALS INC (KYTH): Free Stock Analysis Report
Zacks Investment Research
- Finance Trading
- Personal Investing Ideas & Strategies